A Phase 1b/2a, Multicenter, Open-Label Study of Pocenbrodib as Monotherapy and in combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Sponsor
Pathos AI